US biotech company Novavax (Nasdaq: NVAX), a specialist in protein-based vaccines, has secured UK approval for its updated COVID-19 jab, Nuvaxovid.
The British medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), made the decision based on non-clinical data showing functional immune responses for three new variants.
The company said these data indicate its vaccine can “stimulate both arms of the immune system and induce a broad response against circulating variants.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze